BioMedix SA. to Present at Medtech Insight and Windhover Information's ``In3 Medical Device Summit'' Conference, June 21-23, 2006, in San Francisco, CA.

SAN FRANCISCO -- Biomedix SA. (www.thegard.com) has announced that it will be presenting on Thursday at 2:40 p.m. PT at Medtech Insight and Windhover Information's "In3 Medical Device Summit" Conference, June 21-23, 2006, at The Palace Hotel in San Francisco, Calif.

Biomedix is developing medical devices in the field of gastroenterology concentrating on GERD (Gastro-Esophageal Reflux Disease) and obesity. These represent two of the most common medical issues in the U.S. and Europe -- up to 10% of the Western population suffers daily heartburn. Approximately 60 million Americans are clinically categorized as obese.

The GARD(TM) (Gastro-esophageal Anti-Reflux Device) is made of a medical grade patented soft tubular valve attached through the mouth under endoscopic control in the lower esophagus or hiatus hernia, with endoscopically placed patented new reversible clips. It will replace surgery for reflux esophagitis (Nissen fundoplication) and/or long term medical therapy with Proton Pump Inhibitors (PPIs). The GARD(TM) is the only endoscopic treatment that effectively blocks acid and bile reflux, reducing the risk of cancer of the esophagus (adenocacinoma). As a non-invasive procedure, the GARD presents a superior treatment option to existing alternatives, and will reduce both clinical time and overall treatment cost. The valve can be extended further into the stomach, to reduce the volume of food that can be accommodated, and is an alternative to stomach-stapling procedures for cases of severe obesity.

Biomedix is currently planning trials in the U.S. and Europe. The company, headquartered in Switzerland, is privately funded and is at present looking to form a strategic partnership to assist in further product development.